inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. can benefit from passive immunization with antibodies 3. medically stable 4. negative result from point of care sars-cov-2 serology testing at screening 5. contraceptive used by women of child bearing potential, condom used by men 6. able to understand and comply with study requirements/procedures based on the assessment of the investigator sub-study inclusion criteria which are additional to those in parent study are as follows: * the participant has been randomized, dosed, and is ongoing in the provent parent study and is 12±2 months post first dose of blinded imp. * if one or more of the following apply: 1. immunocompromised and/or may be at increased risk for an inadequate immune response to a covid-19 vaccine. 2. in the opinion of the investigator, are at increased risk and would benefit from a repeat dose of azd7442. * documented negative sars-cov-2 rt-pcr test collected ≤ 3 days prior to sub-study day 1 or a negative rapid sars-cov-2 antigen test at screening.

inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. can benefit from passive immunization with antibodies 3. medically stable 4. negative result from point of care sars-cov-2 serology testing at screening 5. contraceptive used by women of child bearing potential, condom used by men 6. able to understand and comply with study requirements/procedures based on the assessment of the investigator sub-study inclusion criteria which are additional to those in parent study are as follows: * the participant has been randomized, dosed, and is ongoing in the provent parent study and is 12±2 months post first dose of blinded imp. * if one or more of the following apply: 1. immunocompromised and/or may be at increased risk for an inadequate immune response to a covid-19 vaccine. 2. in the opinion of the investigator, are at increased risk and would benefit from a repeat dose of azd7442. * documented negative sars-cov-2 rt-pcr test collected ≤ 3 days prior to sub-study day 1 or a negative rapid sars-cov-2 antigen test at screening.

inclusion criteria: ≥ 18 years of age at the time of signing the informed consent can benefit from passive immunization with antibodies medically stable negative result from point of care sars-cov-2 serology testing at screening contraceptive used by women of child bearing potential, condom used by men able to understand and comply with study requirements/procedures based on the assessment of the investigator sub-study inclusion criteria which are additional to those in parent study are as follows: the participant has been randomized, dosed, and is ongoing in the provent parent study and is 12±2 months post first dose of blinded imp. if one or more of the following apply: immunocompromised and/or may be at increased risk for an inadequate immune response to a covid-19 vaccine. in the opinion of the investigator, are at increased risk and would benefit from a repeat dose of azd7442. documented negative sars-cov-2 rt-pcr test collected ≤ 3 days prior to sub-study day 1 or a negative rapid sars-cov-2 antigen test at screening.

inclusion criteria: ≥ 18 years of age at the time of signing the informed consent can benefit from passive immunization with antibodies medically stable negative result from point of care sars-cov-2 serology testing at screening contraceptive used by women of child bearing potential, condom used by men able to understand and comply with study requirements/procedures based on the assessment of the investigator sub-study inclusion criteria which are additional to those in parent study are as follows: the participant has been randomized, dosed, and is ongoing in the provent parent study and is 12±2 months post first dose of blinded imp. if one or more of the following apply: immunocompromised and/or may be at increased risk for an inadequate immune response to a covid-19 vaccine. in the opinion of the investigator, are at increased risk and would benefit from a repeat dose of azd7442. documented negative sars-cov-2 rt-pcr test collected ≤ 3 days prior to sub-study day 1 or a negative rapid sars-cov-2 antigen test at screening.

inclusion criteria: ≥ 18 years of age at the time of signing the informed consent can benefit from passive immunization with antibodies medically stable negative result from point of care sars-cov-2 serology testing at screening contraceptive used by women of child bearing potential, condom used by men able to understand and comply with study requirements/procedures based on the assessment of the investigator

inclusion criteria: ≥ 18 years of age at the time of signing the informed consent can benefit from passive immunization with antibodies medically stable negative result from point of care sars-cov-2 serology testing at screening contraceptive used by women of child bearing potential, condom used by men able to understand and comply with study requirements/procedures based on the assessment of the investigator

inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. can benefit from passive immunization with antibodies 3. medically stable 4. negative result from point of care sars-cov-2 serology testing at screening 5. contraceptive used by women of child bearing potential, condom used by men 6. able to understand and comply with study requirements/procedures based on the assessment of the investigator

inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. can benefit from passive immunization with antibodies 3. medically stable 4. negative result from point of care sars-cov-2 serology testing at screening 5. contraceptive used by women of child bearing potential, condom used by men 6. able to understand and comply with study requirements/procedures based on the assessment of the investigator

inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. can benefit from passive immunization with antibodies 3. medically stable 4. contraceptive used by women of child bearing potential, condom used by men

inclusion criteria: 1. ≥ 18 years of age at the time of signing the informed consent 2. can benefit from passive immunization with antibodies 3. medically stable 4. contraceptive used by women of child bearing potential, condom used by men